QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:VERV

Verve Therapeutics (VERV) Stock Forecast, Price & News

$17.95
+1.21 (+7.23%)
(As of 06/6/2023 ET)
Compare
Today's Range
$16.68
▼
$18.19
50-Day Range
$13.34
▼
$18.41
52-Week Range
$10.70
▼
$43.00
Volume
633,229 shs
Average Volume
687,537 shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.63
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Verve Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
114.0% Upside
$38.63 Price Target
Short Interest
Bearish
31.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Verve Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.50) to ($3.84) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

662nd out of 984 stocks

Pharmaceutical Preparations Industry

316th out of 472 stocks

See Top Rated MarketRank™ Stocks Here

VERV stock logo

About Verve Therapeutics (NASDAQ:VERV) Stock

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Stock News Headlines

June 5, 2023 | fortune.com
Exclusive: GV promotes 4 new general partners as the firm gears up for ‘the next 15 years’
June 1, 2023 | fool.com
Verve Therapeutics (NASDAQ: VERV)
June 6, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
June 1, 2023 | finance.yahoo.com
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
May 23, 2023 | finance.yahoo.com
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day
May 21, 2023 | americanbankingnews.com
Cantor Fitzgerald Analysts Lower Earnings Estimates for Verve Therapeutics, Inc. (NASDAQ:VERV)
May 20, 2023 | americanbankingnews.com
Q2 2023 EPS Estimates for Verve Therapeutics, Inc. (NASDAQ:VERV) Lowered by William Blair
May 18, 2023 | bizjournals.com
Boston Business Journal unveils 2023 CFOs of the Year
June 6, 2023 | Behind the Markets (Ad)
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
May 18, 2023 | seekingalpha.com
Verve Therapeutics (VERV) Presents at TIDES 2023 - Slideshow
May 18, 2023 | americanbankingnews.com
Verve Therapeutics (NASDAQ:VERV) Posts Earnings Results, Misses Expectations By $0.07 EPS
May 18, 2023 | americanbankingnews.com
Verve Therapeutics (NASDAQ:VERV) Trading Down 7.8% After Earnings Miss
May 17, 2023 | americanbankingnews.com
Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $38.63
May 16, 2023 | msn.com
RBC Capital Reiterates Verve Therapeutics (VERV) Outperform Recommendation
May 15, 2023 | markets.businessinsider.com
LifeSci Capital Remains a Buy on Verve Therapeutics (VERV)
May 15, 2023 | finance.yahoo.com
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
May 15, 2023 | finance.yahoo.com
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
May 11, 2023 | finance.yahoo.com
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
May 9, 2023 | finance.yahoo.com
Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
April 26, 2023 | americanbankingnews.com
Verve Therapeutics (NASDAQ:VERV) Trading Down 4.4%
April 20, 2023 | markets.businessinsider.com
LifeSci Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)
April 20, 2023 | finance.yahoo.com
Top 10 CRISPR Stocks To Buy
April 20, 2023 | americanbankingnews.com
Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $38.63 Average Target Price from Analysts
April 18, 2023 | seekingalpha.com
VERV Verve Therapeutics, Inc.
April 15, 2023 | americanbankingnews.com
Verve Therapeutics (NASDAQ:VERV) Trading Up 7.6%
April 14, 2023 | seekingalpha.com
Verve: Spiffy Biotech That Cathie Wood Bought, Initiating With A Hold Rating
April 14, 2023 | msn.com
Canaccord Genuity Initiates Coverage of Verve Therapeutics (VERV) with Buy Recommendation
See More Headlines

VERV Price History

VERV Company Calendar

Last Earnings
5/15/2023
Today
6/06/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VERV
CUSIP
N/A
CIK
1840574
Web
vervetx.com
Phone
617-603-0070
Fax
N/A
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.63
High Stock Price Forecast
$62.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+114.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-157,390,000.00
Net Margins
N/A
Pretax Margin
-5,355.54%
Return on Equity
-37.63%
Return on Assets
-31.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.43
Quick Ratio
15.43

Sales & Book Value

Annual Sales
$1.94 million
Price / Sales
576.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.94 per share
Price / Book
2.02

Miscellaneous

Outstanding Shares
61,920,000
Free Float
48,668,000
Market Cap
$1.12 billion
Optionable
Not Optionable
Beta
1.46

Key Executives

  • Dr. Sekar Kathiresan M.D. (Age 50)
    Co-Founder, CEO & Director
    Comp: $986.58k
  • Dr. Anthony Philippakis M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Ms. Allison Dorval (Age 46)
    CFO & Principal Accounting Officer
    Comp: $260.93k
  • Dr. Andrew Bellinger M.D. (Age 44)
    Ph.D., Chief Scientific Officer & Chief Medical Officer
    Comp: $727.2k
  • Mr. Andrew D. Ashe J.D.Mr. Andrew D. Ashe J.D. (Age 55)
    Pres & COO
  • Dr. Kiran Musunuru M.D.
    M.P.H., Ph.D., Co-Founder & Sr. Scientific Advisor
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Barry S. Ticho FACC (Age 61)
    M.D., Ph.D., Co-Founder
  • Mr. Issi Rozen M.B.A.
    Co-Founder & Strategic Advisor
  • Ms. Margaret Beaudoin (Age 53)
    VP of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VERV Stock - Frequently Asked Questions

Should I buy or sell Verve Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VERV shares.
View VERV analyst ratings or view top-rated stocks.

What is Verve Therapeutics' stock price forecast for 2023?

8 Wall Street research analysts have issued 1 year price objectives for Verve Therapeutics' stock. Their VERV share price forecasts range from $13.00 to $62.00. On average, they expect the company's stock price to reach $38.63 in the next twelve months. This suggests a possible upside of 114.0% from the stock's current price.
View analysts price targets for VERV or view top-rated stocks among Wall Street analysts.

How have VERV shares performed in 2023?

Verve Therapeutics' stock was trading at $19.35 on January 1st, 2023. Since then, VERV stock has decreased by 6.7% and is now trading at $18.05.
View the best growth stocks for 2023 here.

When is Verve Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VERV earnings forecast.

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.77) by $0.07. The firm earned $1.40 million during the quarter, compared to the consensus estimate of $1 million.

What ETFs hold Verve Therapeutics' stock?

ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and ARK Innovation ETF (ARKK).

When did Verve Therapeutics IPO?

(VERV) raised $201 million in an IPO on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO.

What is Verve Therapeutics' stock symbol?

Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV."

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (11.03%), ARK Investment Management LLC (7.25%), BlackRock Inc. (5.73%), State Street Corp (5.41%), Federated Hermes Inc. (3.88%) and JPMorgan Chase & Co. (3.08%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan.
View institutional ownership trends.

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verve Therapeutics' stock price today?

One share of VERV stock can currently be purchased for approximately $18.05.

How much money does Verve Therapeutics make?

Verve Therapeutics (NASDAQ:VERV) has a market capitalization of $1.12 billion and generates $1.94 million in revenue each year. The company earns $-157,390,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis.

How many employees does Verve Therapeutics have?

The company employs 113 workers across the globe.

How can I contact Verve Therapeutics?

The official website for the company is vervetx.com. The company can be reached via phone at 617-603-0070 or via email at ir@vervetx.com.

This page (NASDAQ:VERV) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -